Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. Its pipeline includes products from two primary families of compounds: Protectans, which are being developed as drug candidates that protect normal tissues from acute stresses, such as radiation, chemotherapy and ischemias; and Curaxins, which are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies. The company was founded by Andrei V. Gudkov on June 5, 2003 and is headquartered in Buffalo, NY.